MMV 390048

Drug Profile

MMV 390048

Alternative Names: MMV 048; MMV390048

Latest Information Update: 07 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Griffith University; University of Cape Town
  • Developer Medicines for Malaria Venture; Technology Innovation Agency; University of Cape Town
  • Class Aminopyridines; Antimalarials; Small molecules
  • Mechanism of Action 1-phosphatidylinositol 4-kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Malaria

Most Recent Events

  • 21 Apr 2018 Efficacy, adverse events and pharmacokinetic data from two phase Ib trials in Malaria presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2018)
  • 02 Feb 2018 Medicines for Malaria Venture withdraws a phase I trial for Malaria (Prevention) in Germany prior to enrolment, for repositioning of target indication (PO) (NCT03195387)
  • 13 Dec 2017 Medicines for Malaria Venture suspends patient enrolment in a phase I trial for Malaria (Prevention) in Germany due to pending analysis of intermediary data (PO) (NCT03195387)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top